197 related articles for article (PubMed ID: 36826464)
1. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
2. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell AR; Huang H; Liao D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer.
Waddell A; Mahmud I; Ding H; Huo Z; Liao D
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199844
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
5. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
[TBL] [Abstract][Full Text] [Related]
7. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.
Fu M; Wang C; Reutens AT; Wang J; Angeletti RH; Siconolfi-Baez L; Ogryzko V; Avantaggiati ML; Pestell RG
J Biol Chem; 2000 Jul; 275(27):20853-60. PubMed ID: 10779504
[TBL] [Abstract][Full Text] [Related]
8. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Ching-Yi Tien J; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 activates androgen receptor through CBP/p300.
Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
[TBL] [Abstract][Full Text] [Related]
10. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells.
Ianculescu I; Wu DY; Siegmund KD; Stallcup MR
J Biol Chem; 2012 Feb; 287(6):4000-13. PubMed ID: 22174411
[TBL] [Abstract][Full Text] [Related]
11. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
12. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
Kim J; Jia L; Stallcup MR; Coetzee GA
J Mol Endocrinol; 2005 Feb; 34(1):107-18. PubMed ID: 15691881
[TBL] [Abstract][Full Text] [Related]
13. Genomic occupancy of the transcriptional co-activators p300 and CBP.
Holmqvist PH; Mannervik M
Transcription; 2013; 4(1):18-23. PubMed ID: 23131664
[TBL] [Abstract][Full Text] [Related]
14. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
15. Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.
Martire S; Nguyen J; Sundaresan A; Banaszynski LA
BMC Mol Cell Biol; 2020 Jul; 21(1):55. PubMed ID: 32690000
[TBL] [Abstract][Full Text] [Related]
16. CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.
Yuan X; Hao X; Chan HL; Zhao N; Pedroza DA; Liu F; Le K; Smith AJ; Calderon SJ; Lieu N; Soth MJ; Jones P; Zhang XH; Rosen JM
bioRxiv; 2024 Apr; ():. PubMed ID: 38712292
[TBL] [Abstract][Full Text] [Related]
17. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
[TBL] [Abstract][Full Text] [Related]
18. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]